OncoCyte Corporation, a molecular diagnostics company, researches, develops, and commercializes proprietary laboratory-developed tests for the detection of cancer in the United States and internationally. The company offers DetermaRx, a molecular test for early stage adenocarcinoma of the lung; and DetermaIO, a proprietary gene expression assay. It also provides custom drug target discovery; assay design, development, and validation; and clinical trial and other testing services for pharmaceutical companies. OncoCyte Corporation has a strategic collaboration with Gruppo Oncologico del Nord-Ovest of Pisa to evaluate DetermaIO as a biomarker for immunotherapy response in metastatic colorectal cancer; and Echelon Diagnostics, Inc. The company was founded in 2009 and is headquartered in Irvine, California.
IPO Year:
Exchange: AMEX
Website: oncocyte.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 5/24/2022 | Overweight → Equal-Weight | Stephens | |
| 3/14/2022 | Overweight → Sector Weight | KeyBanc Capital Markets | |
| 3/11/2022 | $11.00 → $6.00 | Buy | Lake Street |
| 3/11/2022 | $5.00 → $4.00 | Buy | Needham |
| 1/7/2022 | $3.10 | Overweight | Stephens & Co. |
| 1/6/2022 | $3.10 | Overweight | Piper Sandler |
| 12/16/2021 | $7.00 → $5.00 | Buy | Needham |
| 11/10/2021 | $8.00 → $7.00 | Buy | Needham |
Transplant centers representing about 9% of German transplant volumes and about 2% of U.S. transplant volumes have signed on to use GraftAssure kitted research test in early launch phaseFDA pre-submission process for approval of kitted clinical test is underway IRVINE, Calif., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Oncocyte Corporation (NASDAQ:OCX) ("Oncocyte" or the "Company"), a diagnostics technology company, today published the following letter to shareholders in conjunction with its third quarter results: Fellow Shareholders, We are pleased to report that we are making considerable progress on two fronts that help de-risk our path to meaningful revenue. First, we are continuing to sign
IRVINE, Calif., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Oncocyte Corp. (NASDAQ:OCX), a diagnostics technology company, announced today that the company will release its third quarter 2024 financial results on Tuesday, November 12, 2024, after U.S. market closes. The company will also host a conference call and webcast on Tuesday, November 12, 2024, at 2:00 p.m. Pacific Time / 5:00 p.m. Eastern Time to discuss its financial results and highlights. Interested parties may access the live call via telephone by dialing toll free 800-715-9871 for domestic callers. Once dialed in, ask to be joined to the Oncocyte Corporation call. The live webcast of the call may be accessed by visiting the "Even
IRVINE, Calif., Oct. 16, 2024 (GLOBE NEWSWIRE) -- Oncocyte Corp. (NASDAQ:OCX), a diagnostics technology company, announced today that CEO Josh Riggs is scheduled to present at the 17th annual Main Event, hosted by LD Micro, on Tuesday, October 29th in Los Angeles. Oncocyte management will also be available for one-on-one meetings with investors. To schedule a one-on-one meeting, please contact Julie Silber at PCG Advisory ([email protected]) or request a meeting via the LD Micro Conference platform. Event: LD Micro Main Event XVIIDate: Tuesday, October 29thPresentation Time: 2:30 PM PTLocation: The Luxe Sunset Boulevard Hotel, Los Angeles To register to watch the virtual presentat
Results published in peer-reviewed journal, Clinical Cancer Research Study validates DetermaIO's utility in identifying breast cancer patients most likely to benefit from atezolizumab DetermaIO targets a multi-billion-dollar addressable market in oncology diagnostics IRVINE, Calif., Oct. 08, 2024 (GLOBE NEWSWIRE) -- Oncocyte Corp. (NASDAQ:OCX), a diagnostics technology company, announced the peer-reviewed publication of positive data related to its proprietary gene expression test, DetermaIO™. The NeoTRIP Phase 2 clinical trial (NCT002620280) randomized patients with triple-negative breast cancer (TNBC) to receive neoadjuvant carboplatin and nab-paclitaxel (chemotherapies to s
GraftAssure™ research assay adopted by two research hospitals that are top-five-in-country by organ transplant volumeCompany clears first stage gate in clinical product development process and has submitted a Q-Sub to the FDA IRVINE, Calif., Oct. 02, 2024 (GLOBE NEWSWIRE) -- Oncocyte Corporation (NASDAQ:OCX) ("Oncocyte" or the "Company"), a diagnostics technology company, today announced that its new customers include two leading transplant university hospitals in the U.S. and Germany. Both have entered into agreements with the Company to utilize GraftAssure™, the Company's research-use-only assay ("GraftAssure") that can detect early evidence of graft organ damage in patients' blood. On
IRVINE, Calif., Oct. 02, 2024 (GLOBE NEWSWIRE) -- Oncocyte Corporation (NASDAQ:OCX) ("Oncocyte" or the "Company"), a diagnostics technology company, today announced that it has entered into a securities purchase agreement (the "Purchase Agreement") with new and existing investors, including Bio-Rad Laboratories, Inc., one of the Company's strategic partners. The gross proceeds to the Company from the private placement are expected to be approximately $10.2 million, before deducting the placement agent's fees and other offering expenses payable by the Company. The Company intends to use the net proceeds for working capital and general corporate purposes. The Purchase Agreement represents
NEW YORK, Aug. 20, 2024 (GLOBE NEWSWIRE) -- PRISM MarketView announces the release of an illuminating interview with Oncocyte (NASDAQ:OCX) CFO Andrea S. James, who sheds light on her personal career path and the experiences that led to her senior role with the molecular diagnostics technology company. Oncocyte is a market disruptor with a mission to democratize access to molecular diagnostic testing to improve patient outcomes. The company is investing in developing products to serve the separate verticals of organ transplant testing and oncology. James states, "I built my career on the concept of disruptive technology, and I believe that what Oncocyte is offering is truly disruptive in i
IRVINE, Calif., Aug. 12, 2024 (GLOBE NEWSWIRE) -- Oncocyte Corp. (NASDAQ:OCX), a molecular diagnostics technology company, announced the recent publication of a case series of two kidney transplant patients who were monitored for antibody-mediated rejection (AMR) using its proprietary VitaGraft™ Kidney diagnostic test. Patients were tested before, during and after treatment with daratumumab, an anti-CD38 monoclonal antibody1. The study underscores the significant potential of using repeated VitaGraft Kidney measurements to monitor the efficacy of anti-CD38 therapy. VitaGraft Kidney is a noninvasive biomarker2 that quantifies the concentration of donor kidney DNA in the patient's blood af
Interest in kidney transplant assay represents approximately 25% of US transplant volumeCompany lays out land and expand strategy in transplant IRVINE, Calif., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Oncocyte Corp. (NASDAQ:OCX), a diagnostics technology company, today published its second quarter 2024 results and the following letter to shareholders. Dear shareholders,We are thrilled to report that we have successfully launched GraftAssure™, which is our research-use-only assay that can detect early evidence of graft organ damage in a patient's blood. On July 11, 2024, our GraftAssure assay was run at a major metropolitan transplant center and research university in the northeast United State
IRVINE, Calif., Aug. 05, 2024 (GLOBE NEWSWIRE) -- Oncocyte Corp. (NASDAQ:OCX), a molecular diagnostics technology company, today announced that CEO Josh Riggs and CFO Andrea James plan to participate in the following investor conferences in August: 9th Annual Needham Virtual MedTech & Diagnostics 1×1 Conference, August 12-13, 2024. Oncocyte management plans to host meetings with investors. Sidoti Micro-Cap Virtual Conference, August 14-15, 2024. The company is scheduled to present on Wednesday, August 14, from 1:00 PM to 1:30 PM ET in Track 3, as well as participate in one-on-one meetings. To join the presentation, please visit the webcast available online at: https://sidoti.zoom.us/we
10-Q - Oncocyte Corp (0001642380) (Filer)
8-K - Oncocyte Corp (0001642380) (Filer)
424B3 - Oncocyte Corp (0001642380) (Filer)
EFFECT - Oncocyte Corp (0001642380) (Filer)
S-3/A - Oncocyte Corp (0001642380) (Filer)
S-3 - Oncocyte Corp (0001642380) (Filer)
8-K - Oncocyte Corp (0001642380) (Filer)
D - Oncocyte Corp (0001642380) (Filer)
8-K - Oncocyte Corp (0001642380) (Filer)
DEF 14A - Oncocyte Corp (0001642380) (Filer)
4 - Oncocyte Corp (0001642380) (Issuer)
4 - Oncocyte Corp (0001642380) (Issuer)
4 - Oncocyte Corp (0001642380) (Issuer)
4 - Oncocyte Corp (0001642380) (Issuer)
4 - Oncocyte Corp (0001642380) (Issuer)
Late-breaking presentation of data at American Transplant Congress on Monday, June 3Data show potential to monitor for therapeutic efficacy and recurrencePotential repeat testing opportunities with claims expansionIRVINE, Calif., May 30, 2024 (GLOBE NEWSWIRE) -- Oncocyte Corporation (NASDAQ:OCX), a precision diagnostics company, today announced that favorable data regarding its lead product VitaGraft™ Kidney was published in the New England Journal of Medicine. Oncocyte's Drs. Ekke Schuetz and Julia Beck, inventors of the technology, are among the authors of the study. VitaGraft Kidney was used to monitor graft injury in a phase 2 double-blind, placebo-controlled study (NCT05021484) of the i
Analysts' ratings for OncoCyte (NASDAQ:OCX) over the last quarter vary from bullish to bearish, as provided by 4 analysts. The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 2 1 1 0 0 Last 30D 1 0 0 0 0 1M Ago 1 0 1 0 0 2M Ago 0 1 0 0 0 3M Ago 0 0 0 0 0 Analysts have set 12-month price targets for OncoCyte, revealing an average target of $4.38, a high estimate of $5.00, and a low estimate of $4.00. This upward trend is evident, with the current average reflecting a 21.67% increase from the previous
Needham analyst Mike Matson reiterates OncoCyte (NASDAQ:OCX) with a Buy and maintains $4.25 price target.
OncoCyte (NASDAQ:OCX) reported quarterly losses of $(1.13) per share which missed the analyst consensus estimate of $(0.67) by 68.66 percent. This is a 237.8 percent decrease over earnings of $0.82 per share from the same period last year. The company reported quarterly sales of $176.000 thousand which missed the analyst consensus estimate of $350.000 thousand by 49.71 percent. This is a 40.74 percent decrease over sales of $297.000 thousand the same period last year.
Needham analyst Mike Matson maintains OncoCyte (NASDAQ:OCX) with a Buy and raises the price target from $3.6 to $4.25.
Gainers ImmunityBio (NASDAQ:IBRX) shares moved upwards by 32.0% to $6.52 during Tuesday's pre-market session. The company's market cap stands at $4.4 billion. Nuwellis (NASDAQ:NUWE) shares increased by 24.1% to $0.41. The market value of their outstanding shares is at $2.8 million. VolitionRX (AMEX:VNRX) stock increased by 16.66% to $0.7. The company's market cap stands at $57.4 million. Tiziana Life Sciences (NASDAQ:TLSA) shares increased by 15.47% to $0.87. The market value of their outstanding shares is at $87.2 million. Ontrak (NASDAQ:OTRK) stock moved upwards by 14.46% to $0.34. The market value of their outstanding shares is at $16.1 million. NKGen Biotech (NASDAQ:NKGN) shares in
- SEC Filing
Stephens & Co. analyst Mason Carrico reiterates OncoCyte (NASDAQ:OCX) with a Equal-Weight and maintains $4 price target.
Stephens downgraded OncoCyte from Overweight to Equal-Weight
KeyBanc Capital Markets downgraded OncoCyte from Overweight to Sector Weight
Lake Street reiterated coverage of OncoCyte with a rating of Buy and set a new price target of $6.00 from $11.00 previously
Needham reiterated coverage of OncoCyte with a rating of Buy and set a new price target of $4.00 from $5.00 previously
Stephens & Co. initiated coverage of OncoCyte with a rating of Overweight and set a new price target of $3.10
Piper Sandler resumed coverage of OncoCyte with a rating of Overweight and set a new price target of $3.10
Needham reiterated coverage of OncoCyte with a rating of Buy and set a new price target of $5.00 from $7.00 previously
Needham reiterated coverage of OncoCyte with a rating of Buy and set a new price target of $7.00 from $8.00 previously
Needham resumed coverage of OncoCyte with a rating of Buy and set a new price target of $8.00
SC 13G - Oncocyte Corp (0001642380) (Subject)
SC 13G/A - Oncocyte Corp (0001642380) (Subject)
SC 13G - Oncocyte Corp (0001642380) (Subject)
SC 13G - Oncocyte Corp (0001642380) (Subject)
SC 13D/A - Oncocyte Corp (0001642380) (Subject)
SC 13G/A - Oncocyte Corp (0001642380) (Subject)
SC 13G/A - Oncocyte Corp (0001642380) (Subject)
SC 13G/A - Oncocyte Corp (0001642380) (Subject)
SC 13D/A - Oncocyte Corp (0001642380) (Subject)
SC 13G/A - Oncocyte Corp (0001642380) (Subject)
4 - Oncocyte Corp (0001642380) (Issuer)
4 - Oncocyte Corp (0001642380) (Issuer)
4 - Oncocyte Corp (0001642380) (Issuer)
4 - Oncocyte Corp (0001642380) (Issuer)
4 - Oncocyte Corp (0001642380) (Issuer)
4 - Oncocyte Corp (0001642380) (Issuer)
4 - Oncocyte Corp (0001642380) (Issuer)
3 - Oncocyte Corp (0001642380) (Issuer)
4 - Oncocyte Corp (0001642380) (Issuer)
4 - Oncocyte Corp (0001642380) (Issuer)
Transplant centers representing about 9% of German transplant volumes and about 2% of U.S. transplant volumes have signed on to use GraftAssure kitted research test in early launch phaseFDA pre-submission process for approval of kitted clinical test is underway IRVINE, Calif., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Oncocyte Corporation (NASDAQ:OCX) ("Oncocyte" or the "Company"), a diagnostics technology company, today published the following letter to shareholders in conjunction with its third quarter results: Fellow Shareholders, We are pleased to report that we are making considerable progress on two fronts that help de-risk our path to meaningful revenue. First, we are continuing to sign
IRVINE, Calif., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Oncocyte Corp. (NASDAQ:OCX), a diagnostics technology company, announced today that the company will release its third quarter 2024 financial results on Tuesday, November 12, 2024, after U.S. market closes. The company will also host a conference call and webcast on Tuesday, November 12, 2024, at 2:00 p.m. Pacific Time / 5:00 p.m. Eastern Time to discuss its financial results and highlights. Interested parties may access the live call via telephone by dialing toll free 800-715-9871 for domestic callers. Once dialed in, ask to be joined to the Oncocyte Corporation call. The live webcast of the call may be accessed by visiting the "Even
Interest in kidney transplant assay represents approximately 25% of US transplant volumeCompany lays out land and expand strategy in transplant IRVINE, Calif., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Oncocyte Corp. (NASDAQ:OCX), a diagnostics technology company, today published its second quarter 2024 results and the following letter to shareholders. Dear shareholders,We are thrilled to report that we have successfully launched GraftAssure™, which is our research-use-only assay that can detect early evidence of graft organ damage in a patient's blood. On July 11, 2024, our GraftAssure assay was run at a major metropolitan transplant center and research university in the northeast United State
IRVINE, Calif., Aug. 01, 2024 (GLOBE NEWSWIRE) -- Oncocyte Corp. (NASDAQ:OCX), a diagnostics technology company, announced today that the company will release its second quarter 2024 financial results on Thursday, August 8, 2024, after U.S. market close. The company will host a conference call and webcast on Thursday, August 8, 2024, at 5:00 p.m. Eastern Time to discuss its financial results and highlights. Interested parties may access the live call via telephone by dialing toll free 800-715-9871 for domestic callers. Once dialed in, ask to be joined to the Oncocyte Corporation call. The live webcast of the call may be accessed by visiting the "Events & Presentations" section of the Com
Late-breaking presentation of data at American Transplant Congress on Monday, June 3Data show potential to monitor for therapeutic efficacy and recurrencePotential repeat testing opportunities with claims expansion IRVINE, Calif., May 30, 2024 (GLOBE NEWSWIRE) -- Oncocyte Corporation (NASDAQ:OCX), a precision diagnostics company, today announced that favorable data regarding its lead product VitaGraft™ Kidney was published in the New England Journal of Medicine. Oncocyte's Drs. Ekke Schuetz and Julia Beck, inventors of the technology, are among the authors of the study. VitaGraft Kidney was used to monitor graft injury in a phase 2 double-blind, placebo-controlled study (NCT05021484) of t
IRVINE, Calif., May 15, 2024 (GLOBE NEWSWIRE) -- Oncocyte Corporation (NASDAQ:OCX), a precision diagnostics company, today reported financial results for the quarter ended March 31, 2024. Recent Highlights Announced global commercialization partnership with Bio-Rad Laboratories, Inc.On track to ship research use only (RUO) GraftAssure™ transplant monitoring test kits to initial customers in Asia, the U.S., and the EU in 2Q 2024. IVD kits are under development for FDA submission.Raised $15.8 million in gross proceeds from equity private placement; as part of the financing, Bio-Rad purchased 8.99% of Oncocyte; new and existing investors invested as well.Reduced cash burn to $3.9 million, r
IRVINE, Calif., May 13, 2024 (GLOBE NEWSWIRE) -- Oncocyte Corporation (NASDAQ:OCX), a precision diagnostics company, announced today that the company will release its first quarter 2024 financial results on Wednesday, May 15, 2024, after U.S. market close. The company will host a conference call and webcast on Wednesday, May 15, 2024, at 4:30 p.m. Eastern Time to discuss its financial results and highlights. Interested parties may access the live call via telephone by dialing toll free (800) 715-9871 for both domestic and international callers. Once dialed in, ask to be joined to the Oncocyte Corporation call. The live webcast of the call may be accessed by visiting the "Events & Present
IRVINE, Calif., April 12, 2024 (GLOBE NEWSWIRE) -- Oncocyte Corporation (NASDAQ:OCX), a precision diagnostics company, today reported financial results for the year ended December 31, 2023. Recent Highlights Bio-Rad Laboratories, Inc. commercial partnership for transplant monitoring IP$15.8 million in gross proceeds received from private placement offering$4.4 million and $3.8 million Q4 2023 and est. Q1 2024 cash burn, respectivelyGraftAssure™ transplant product launch on track for 2Q 2024 "In 2023, we made significant progress on cost controls and in the development of our transplant monitoring IP," said Josh Riggs, CEO of Oncocyte. "We achieved reimbursement for VitaGraft™ Kidney, ma
IRVINE, Calif., April 09, 2024 (GLOBE NEWSWIRE) -- Oncocyte Corporation (NASDAQ:OCX), a precision diagnostics company, announced today that the company will release its fourth quarter and full year 2023 financial results on Friday, April 12, 2024, prior to the U.S. market open. The company will host a conference call and webcast on Friday, April 12, 2024, at 5:00 a.m. Pacific Time / 8:00 a.m. Eastern Time to discuss its financial results and highlights. Interested parties may access the live call via telephone by dialing toll free (888) 550-5422 for both domestic and international callers. Once dialed in, ask to be joined to the Oncocyte Corporation call. The live webcast of the call may
-Launching First Products in 1H 2024- -Conference Call on Thursday, November 9, 2023 at 5:00 a.m. PT / 8:00 a.m. ET- IRVINE, Calif., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Oncocyte Corporation (NASDAQ:OCX), a precision diagnostics company, today reported financial results for the third quarter of 2023, ended September 30, 2023. Third Quarter and Recent Highlights VitaGraft™ Kidney, the Company's kidney transplant diagnostic test, received a positive coverage decision from CMS coverage; commercial revenue is expected beginning in 1H 2024.Significant new clinical data was presented at the European Society of Organ Transplant Conference demonstrating the VitaGraft assay detects antibody-mediat
NEW YORK, June 24, 2024 (GLOBE NEWSWIRE) -- PRISM MarketView, a leader within the financial markets and news community, announces the release of an article highlighting the precision diagnostics company, Oncocyte's (NASDAQ:OCX) appointment of leading finance executive, Andrea James, as Chief Financial Officer. This strategic move comes at a pivotal time as Oncocyte prepares for significant commercial and regulatory milestones expected in 2024 and 2025. Under the leadership of CEO Josh Riggs, Oncocyte is poised for a transformative period with its upcoming commercial launches. The company's flagship products, the VitaGraft™ Kidney diagnostic test and its research use only (RUO) GraftAssure
IRVINE, Calif., June 17, 2024 (GLOBE NEWSWIRE) -- Oncocyte Corporation (NASDAQ:OCX), a precision diagnostics company, today announced that it has appointed leading finance executive, Andrea James, to the position of Chief Financial Officer. "We are thrilled to welcome Andrea as we approach the inflection point of commercial launch," Oncocyte CEO Josh Riggs said. "She has a proven track record of guiding financial strategy through multiple phases of growth, raising and stewarding capital, and building relationships with high quality institutional investors. Andrea is therefore an ideal CFO business partner to myself, the Board of Directors and the Oncocyte team. "We expect 2024 and 2025 t
IRVINE, Calif., March 02, 2023 (GLOBE NEWSWIRE) -- Oncocyte Corporation (NASDAQ:OCX), a precision diagnostics company, today announced that Joshua Riggs has been appointed as its Chief Executive Officer effective February 24, 2023. Since being named interim CEO in December, Riggs has successfully led the process of restructuring the Company by refocusing product strategy and reducing costs across the organization. Riggs also serves as President and joins the Company's Board of Directors. "Since his appointment as Interim CEO, Josh has worked quickly, collaboratively, and effectively to significantly reduce the Company's spend rate, has driven the restructuring of a number of strategic i
IRVINE, Calif., Nov. 30, 2022 (GLOBE NEWSWIRE) -- Oncocyte Corporation (NASDAQ:OCX), a precision diagnostics company with the mission to improve patient outcomes by providing personalized insights that inform critical decisions throughout the patient care journey, today announced the appointment of Louis E. Silverman as an independent member of its board of directors, effective immediately. "I am pleased to announce the appointment of Lou as a member of our Board," said Andy Arno, Chair of Oncocyte's Board of Directors. "Lou's 25+-year track record of success as CEO in health care IT and health care services companies will assuredly be accretive to the Company's strategic goals. We are co
IRVINE, Calif., Aug. 01, 2022 (GLOBE NEWSWIRE) -- Oncocyte Corporation (NASDAQ:OCX), a precision diagnostics company with the mission to improve patient outcomes by providing personalized insights that inform critical decisions throughout the patient care journey, today announced the appointment of John Peter (JP) Gutfreund as an independent member of its board of directors, effective July 28, 2022. "We welcome JP to our Board of Directors at what we believe to be an important time in the life of Oncocyte, as we anticipate bringing three major products through reimbursement and to market over the next four quarters," said Ron Andrews, CEO of Oncocyte. "He brings a wealth of financial expe
IRVINE, Calif., Oct. 07, 2021 (GLOBE NEWSWIRE) -- Oncocyte Corporation (NASDAQ:OCX), a precision diagnostics and monitoring company with the mission to improve patient outcomes by providing clear insights that inform critical decisions in the diagnosis, treatment, and monitoring of cancer, today announced the appointment of Gisela A. Paulsen, MPharm, to the role of Chief Operating Officer (COO). Paulsen brings with her over two decades of experience as a cross-functional leader, with an extensive scientific and operational background leading large-scale global change management and driving commercial and drug development innovation at global pharmaceutical and diagnostics companies. "We